BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3103395)

  • 1. Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease.
    Stern G; Lees A
    Adv Neurol; 1987; 45():525-7. PubMed ID: 3103395
    [No Abstract]   [Full Text] [Related]  

  • 2. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of bromocriptine in the treatment of Parkinson's disease.
    Stern GM; Lees AJ; Shaw KM; Lander CM
    Adv Biochem Psychopharmacol; 1980; 23():267-70. PubMed ID: 7395617
    [No Abstract]   [Full Text] [Related]  

  • 7. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further experiences with low doses of bromocriptine in Parkinson's disease.
    Fahn S; Côté LJ; Barrett RE; Snider SR
    Adv Biochem Psychopharmacol; 1980; 23():255-60. PubMed ID: 7395615
    [No Abstract]   [Full Text] [Related]  

  • 11. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
    Wallis WE
    Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
    Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
    Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
    van der Drift JH
    Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine in Parkinson's disease: report on 106 patients treated for up to 5 years.
    Lieberman AN; Kupersmith M; Neophytides A; Gopinathan G; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():245-53. PubMed ID: 7395614
    [No Abstract]   [Full Text] [Related]  

  • 16. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.